Search

Your search keyword '"G.D.S. Demetri"' showing total 5 results
Start Over Author "G.D.S. Demetri"
5 results on '"G.D.S. Demetri"'

1. A matching-adjusted indirect comparison of trabectedin and pazopanib for the treatment of advanced, metastatic, leiomyosarcomas

Author

Javier Martin-Broto, S. Patel, Robert G. Maki, J.M. Fernandez Santos, Robin L. Jones, G.D.S. Demetri, S. Wang, J.-Y. Blay, George Wang, C.R. Shin, M.J. Pontes, A. Lecesne, and B. García San Andrés

Subjects
Oncology, Pazopanib, medicine.medical_specialty, Matching (statistics), business.industry, Internal medicine, Medicine, Hematology, business, Trabectedin, Indirect comparison, medicine.drug
Published
2017

2. Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) receiving placebo or regorafenib in the phase 3 GRID trial

Author

Christian Kappeler, G.D.S. Demetri, and Anthony D. Wagner

Subjects
Oncology, medicine.medical_specialty, Stromal cell, GiST, business.industry, Hematology, Placebo, chemistry.chemical_compound, chemistry, Internal medicine, Regorafenib, Overall survival, Medicine, Progression-free survival, business
Published
2017

3. Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses

Author

Hans Gelderblom, A. Le Cesne, Qasim Ahmad, G.D.S. Demetri, G. Han, Luca Dezzani, W.T.A. van der Graaf, and Sebastian Bauer

Subjects
Oncology, medicine.medical_specialty, Pathology, business.industry, Hematology, Pazopanib, 03 medical and health sciences, 0302 clinical medicine, Palette (painting), 030220 oncology & carcinogenesis, Internal medicine, medicine, 030212 general & internal medicine, Soft tissue carcinoma, business, medicine.drug
Published
2017

4. Efficacy and safety of trabectedin in an elderly patient subgroup (≥65 years) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) from the Expanded Access Program (EAP)

Author

Robert G. Maki, S. Patel, G.D.S. Demetri, R.L. Jones, George Wang, Roland Elmar Knoblauch, and C.R. Shin

Subjects
0301 basic medicine, Leiomyosarcoma, medicine.medical_specialty, business.industry, General surgery, Hematology, Liposarcoma, medicine.disease, Surgery, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Expanded access, medicine, business, Elderly patient, Trabectedin, medicine.drug
Published
2017

5. Efficacy and safety of patients treated long-term with trabectedin (t) on the expanded access program: A retrospective analysis

Author

S. Patel, Scott M. Schuetze, C.R. Shin, M. Smith, Robert G. Maki, Priscilla Merriam, R.L. Jones, George Wang, Roland Elmar Knoblauch, Elizabeth J. Davis, and G.D.S. Demetri

Subjects
0301 basic medicine, medicine.medical_specialty, business.industry, Hematology, Surgery, Term (time), 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Expanded access, Emergency medicine, medicine, Retrospective analysis, business, Trabectedin, medicine.drug
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results